Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May 8:5:21.
doi: 10.1186/1756-8722-5-21.

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Gurpreet Lamba  1 , Samir Ambrale, Byung Lee, Ridhi Gupta, Shamudheen M Rafiyath, Delong Liu
Affiliations
Review

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Gurpreet Lamba et al. J Hematol Oncol. .

Abstract

The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomyoma, and leiomyosarcoma are typically CD117-negative. GIST research and clinical care now represent a paradigm of translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that selectively inhibit etiologic "driver" pathways, leading to dramatically improved clinical outcomes. A series of investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review, we discuss the highlights of recent advances and novel agents for GIST therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
KIT (CD117) receptor tyrosine kinase structure and common mutations found in gastrointestinal stromal tumor. Arrows indicate the corresponding mutations in the exons.
Figure 2
Figure 2
KIT (CD117) gene structure and common mutations in gastrointestinal stromal tumor. Arrows indicate the positions of common mutations in the KIT gene.
See this image and copyright information in PMC

References

    1. Rubin BP, Fletcher JA, Fletcher CD. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol. 2000;8(1):5–10. doi: 10.1177/106689690000800105. - DOI - PubMed
    1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP. et al.Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–465. doi: 10.1053/hupa.2002.123545. - DOI - PubMed
    1. Miettinen M, El-Rifai W, L HLS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33(5):478–483. doi: 10.1053/hupa.2002.124123. - DOI - PubMed
    1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M. et al.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–580. doi: 10.1126/science.279.5350.577. - DOI - PubMed
    1. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A. et al.PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–710. doi: 10.1126/science.1079666. - DOI - PubMed

Publication types

MeSH terms

Substances